ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years
Haifeng Hu
Matched on ORCID iD 0000-0001-6405-9333; OpenAlex author ID A5064205238. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2021: 2 papers · 2022: none · 2023: none · 2024: 2 papers
Papers 4
- NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3-IFIT3 axis. Co-author DOI 10.1002/mc.23645↗
- SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer. Co-author DOI 10.1038/s41401-023-01199-z↗
- Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Co-author DOI 10.1038/s41401-020-00584-2↗
- ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. Co-author DOI 10.1186/s12935-021-02210-5↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ye Zeng · 4 shared papers, 2021–2024 · strength 0.68
- Paper NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3-IFIT3 axis. DOI 10.1002/mc.23645↗
- Paper SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer. DOI 10.1038/s41401-023-01199-z↗
- Paper Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. DOI 10.1038/s41401-020-00584-2↗
- Xianjun Yu · 4 shared papers, 2021–2024 · strength 0.68
- Paper NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3-IFIT3 axis. DOI 10.1002/mc.23645↗
- Paper SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer. DOI 10.1038/s41401-023-01199-z↗
- Paper Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. DOI 10.1038/s41401-020-00584-2↗
- Shunrong Ji · 4 shared papers, 2021–2024 · strength 0.68
- Paper NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3-IFIT3 axis. DOI 10.1002/mc.23645↗
- Paper SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer. DOI 10.1038/s41401-023-01199-z↗
- Paper Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. DOI 10.1038/s41401-020-00584-2↗
- Yi Qin · 4 shared papers, 2021–2024 · strength 0.68
- Paper NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3-IFIT3 axis. DOI 10.1002/mc.23645↗
- Paper SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer. DOI 10.1038/s41401-023-01199-z↗
- Paper Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. DOI 10.1038/s41401-020-00584-2↗
- Xiaowu Xu · 3 shared papers, 2021–2024 · strength 0.49
- Paper NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3-IFIT3 axis. DOI 10.1002/mc.23645↗
- Paper Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. DOI 10.1038/s41401-020-00584-2↗
- Paper ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. DOI 10.1186/s12935-021-02210-5↗
- Haidi Chen · 2 shared papers, 2021–2024 · strength 0.34
- Borui Li · 1 shared paper, 2024 · strength 0.22
- Hai-di Chen · 1 shared paper, 2024 · strength 0.20
- Chenjie Zhou · 1 shared paper, 2024 · strength 0.20
- Zheng Li · 1 shared paper, 2024 · strength 0.20
- Xiaowu Xu · 1 shared paper, 2024 · strength 0.20
- Qifeng Zhuo · 1 shared paper, 2021 · strength 0.15
- Wenyan Xu · 1 shared paper, 2021 · strength 0.12
- Wensheng Liu · 1 shared paper, 2021 · strength 0.12
- Changfeng Song · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.